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Abstract
Background: Decay-accelerating factor (DAF) and membrane cofactor protein (MCP) are the key
molecules involved in cell protection against autologus complement, which restricts the action of
complement at critical stages of the cascade reaction. The cooperative effect of DAF and MCP on
the survival of human cervical cancer cell (ME180) has not been demonstrated.
Methods: In this study we applied, for the first time, short hairpin RNA (shRNA) to knock down
the expression of the DAF and MCP with the aim of exploiting complement more effectively for
tumor cell damage. Meanwhile, we investigated the cooperative effects of DAF and MCP on the
viability and migration, moreover the proliferation of ME180 cell.
Results: The results showed that shRNA inhibition of DAF and MCP expression enhanced
complement-dependent cytolysis (CDC) up to 39% for MCP and up to 36% for DAF, and the
combined inhibition of both regulators yielded further additive effects in ME180 cells. Thus, the
activities of DAF and MCP, when present together, are greater than the sum of the two protein
individually.
Conclusion: These data indicated that combined DAF and MCP shRNA described in this study
may offer an additional alternative to improve the efficacy of antibody-and complement-based
cancer immunotherapy.
Background
Cervical cancer is the second most common cancer among
women worldwide, with about 470,000 newly diagnosed
cases and almost 250,000 deaths every year [1,2]. Cervical
cancer is the leading cause of death from cancer in many
low-resource countries [3]. The lack of preventive strate-
gies, early diagnostic methods, and effective therapies to
treat recurrent cervical tumors creates a pressing need to
understand its pathogenesis and to identify molecular
markers and targets for diagnosis as well as therapy [4].
The unlimited growth and the metastasis are the impor-
tant traits of the tumor, are the main causes of cancer-
related death induced by the failure of treatment of cervi-
cal cancer [5]. However, the factors that promote malig-
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remain largely unknown.
The complement system has been characterised exten-
sively, both biochemically and functionally. When com-
plement components are deposited on host cells,
complement regulating factors protect autologous cells
from complement mediated cytotoxicity [6]. Antibody-
mediated complement-dependent killing of tumor cells is
not a very efficient effector mechanism, due to the overex-
pression of complement regulatory proteins on tumor
cells, which are protected from complement attack in this
way. Decay-accelerating factor (DAF) and membrane
cofactor protein (MCP) function as cell surface regulators
that serve to protect self cells from attack by autologous
complement. The two proteins complement each other in
that DAF acts to accelerate the decay of the classical and
alternative C3 convertases (C4b2a and C3bBb) [7] while
MCP functions as a cofactor for the factor I-mediated
cleavage of cell-bound C3b and C4b [8]. Although both
proteins have been studied extensively, little is known
about whether and, if so, how they cooperate on cervical
cancer cells surface. Therefore, our present study aimed to
investigate the expression of DAF, MCP and to assess
effect of the protein on cervical cancer cells survival.
Methods
Reagents
Human cervical cancer cell lines ME180 (The level of DAF
and MCP in ME180 was the maximal expression [see
Additional file 1]) was provided by China Centre for Type
Culture Collection. The short hairpin RNA (shRNA) was
synthesized by Wuhan Genesil Biotechnology Co., Ltd
(Wuhan, China). Lipofectamine 2000 was purchased
from Invitrogen (Carlsbad, CA). Phototope-HRP Western
Blot Detection System, including anti-mouse IgG, HRP-
linked antibody, Biotinylated protein ladder, 20× Lumi-
GLO Reagent and 20× Peroxide were purchased from Cell
Signaling Technology (Beverly, MA, USA). The mouse
monoclonal antibodies against decay-accelerating factor
(DAF), membrane cofactor protein (MCP) and β-actin
were purchased from Santa Cruz Biotechonolgy (Santa
Cruz, CA, USA). The 3H-thymidine was endowed by iso-
tope lab of Nanjing Medical University. Trizol reagent was
purchased from life Techology (Gaitherburg, MD, USA).
Human blood was obtained from healthy donors.
Tissue procurement and preparation
Human cervical cancer tissues were collected from 30
patients who underwent radical hysterectomy because of
cervical carcinoma at Nanjing Maternity and Child Health
Care Hospital between October 2004 and January 2007.
Tumor specimens were obtained immediately after sur-
gery. Local ethical approval was obtained before com-
mencing this study and, as appropriate, tissue was
collected with informed consent.
Human cervical cancer cell line culture and DNA 
transfection
The human cervical cancer cells were propagated in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% Fatal Calf Serum (FCS), 100 U/ml penicillin,
100 μg/ml streptomycin, 10% unnecessary amino acid at
37°C in a 5% CO2 incubator. Cells used in experiments
were from 5 to 7 passages. Lipofectin- and oligofectamine-
transfection of shRNA was performed according to the
manufacturer's recommendations. Briefly, to transfect
tumor cells of one well of a six-well plate, each 500 pmol
shRNA and 10 μl lipofectin were diluted in 750 μl Opti-
MEM. After preincubation of the lipofectin solution for 45
min at 37°C, both solution were mixed and incubated for
additional 15 min at room temperature. The lipofectin/
shRNA mixture was subsequently overlaid onto the cells
and incubated for 2 h. Finally, 1 ml growth medium (20%
FCS) per well was added for further cultivation of the
tumor cells. Reporter gene activities were normalized to
total protein, and all results represented the average of
triplicate experiments.
Construction of DAF shRNA-expressing plasmid vector
The complementary oligonucleotides encoded a hairpin
structure with a 19-mer stem derived from the target site,
in this experiment, the targeted short hairpin RNA
(shRNA) sequences for DAF were CTC CAC TGG ACA
GAG CTG CC and MCP were GCG CGG CGC GGA AGA
CGC TG. Two complementary domains were separated by
a 9-bp loop sequence. Near the 3' end of the shRNA tem-
plate was a 6 nucleotide poly (T) tract recognized as a RNA
pol III termination signal. The 5' end of the two oligonu-
cleotides was BamHI and Hind III restriction site over-
hung. The vectors of DAF and MCP shRNA-expressing
plasmid were constructed by using pGenesil-1 as the vec-
tor backbone. The shRNA synthesized and annealed was
ligated into the BamHI and Hind III site of the pGenesil-
1 expression vector. At the same time, we chose an unre-
lated gene shRNA as a negative control.
Western blot analysis
The cells were collected with sample buffer. Whole cell
lysates (50 μg) for each sample were subjected to electro-
phoresis in 10% SDS-polyacrylamide gels. Thereafter, the
protein was blotted onto a PVDF membrane. Primary
antibodies against DAF, MCP and β-actin were used
according to the manufacturer's recommedations. After
washing the membrane, the second antibody (HRP-con-
jugated anti-mouse IgG) was used for the detection of
DAF, MCP and β-actin. The bands were visualized by the
ECL detection system with 5 to 10 min exposure afterPage 2 of 8
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loading control.
C3-deposition
ME180 cells were incubated and subsequently sensitized
by incubation with a rabbit polyclonal anti-ME180 antise-
rum (diluted 1/5) for 20 min on ice. ME180 cells were
washed, resuspended at 3 × 106 cells/ml and 50 μl cells
were mixed with 100 μl of C8-depleted serum (prepared
by passage over an anti-C8 affinity column). After 1 hr
incubation at 37°, complement activation was terminated
by washing cells once with ice-cold EDTA solution (20
mM EDTA/FACS buffer) and two additional times with
FACS buffer. Flow cytofluorometrical analysis, as
described above, was used to quantify C3b binding.
Complement-mediated cytotoxicity
A radioactive cytotoxicity assay was used to measure com-
plement-mediated cytotoxicity. ME180 cell transfectants
were grown to 70% confluency on 100-mm culture plates.
Cells were removed with 4 ml Versene and washed three
times with PBS. A total of 1 × 107 cells then were sus-
pended in 1 ml PBS containing 500 μCi 51Cr, and the cell
suspensions were incubated for 2 h at 37°C with occa-
sional shaking. After washing three times with GVB-E, 5 ×
105 labeled cells were incubated for 15 min at 4°C with
rabbit anti-hamster lymphocyte serum (1:2) in 200 μl of
GVB-E. Cells were washed three more times with GVB2+,
resuspended to 105 cells/ml in GVB2+, and 100-μl aliquots
of the cell suspension added to the wells of 96-well V-bot-
tom plates. Then serial dilutions of normal human serum
were added in 100-μl volumes in triplicate wells for each
cell type. A volume of 100 μl of 1% Triton X-100 and
buffer alone were included as controls for 100% release
and for spontaneous release, respectively. The percent spe-
cific release was calculated from the formula: % specific
release = [(measured release - spontaneous release)/
(100% release - spontaneous release)].
Cell viability assay
We confirmed proliferating activity by water-soluble tetra-
zolium salt (WST-1) assay (Roche Diagnostics, Man-
nheim, Germany). The WST-1 assay is a colorimetric
method in which the dye intensity is proportional to the
number of viable cells. Cells were seeded into 96-well
microtiter plates at a concentration of 5 × 103 cells/well.
After 12-h incubation, cells were treated with different
media for 48 h. After incubation, the cells were washed
with PBS and the cell proliferation reagent WST-1 was
added, then incubated for 4 h. Sample absorbence was
analyzed with a bichromatic ELISA reader at 450 nm. All
experiments were performed in triplicate with different
passages of the ME180 cells.
In vitro migration assay
Cell migration was assayed using 24-mm diameter cham-
bers with 8-μm pore filters (Transwell, 6-well cell culture).
The ME180 cells were removed from the culture flasks and
resuspended at 7.5 × 106 cells/ml in serum-free medium,
and then 0.2 ml cell suspension was added to the upper
chambers. Afterwards, the lower chambers were added
with the different medium (0.5 ml). The chambers were
incubated for 48 hours at 37°C in a humid atmosphere of
5% CO2/95% air. And then the filters were fixed in 95%
ethanol and stained with H.E. The upper surfaces of the
filters were scraped twice with cotton swabs to remove
non-migrated cells. The experiments were repeated in trip-
licate with different passages of the ME180 cells, and the
migrated cells were counted microscopically (400×) in
five different fields per filter.
Measurement of 3H-thymidine incorporation (3H-TdR)
ME180 were plated into 96-well plates and incubated over-
night. Media were removed from the cells and replaced
with 200 μl media, as described in the results section. The
cells were incubated for 54 h, and then DNA synthesis was
determined by 3H-TdR for the final 18 h. The media were
carefully removed and the cells were detached with 50 μl
trypsin-EDTA. The cells were then harvested onto glass fil-
ters with a Tomtech cell harvester and the radioactivity
retained on the dried filters was measured by the addition
of 50 ml scintillation liquid and counted in a TopCount
NxT scintillation counter. All experiments were performed
in triplicate with different passages of the ME180 cells.
Statistical analysis
Most results are presented as means ± SD. Differences
between various data sets were tested for significance
using Student's t-test and p-value of less than 0.05 were
considered significant (*p < 0.05; **p < 0.01; ***p <
0.001).
Results
The complement regulatory protein expression and C3b 
deposition in human cervical cancer tissue
In order to investigate the relationship between comple-
ment regulatory protein and complement-mediated cyto-
toxicity in human cervical cancer cells, the DAF, MCP
expression and C3b deposition of 30 cases human cervical
cancer tissues and surrounding non-neoplastic tissues
were analyzed in this experiment (Figure 1). The expres-
sion of DAF and MCP was significantly increased in
human cervical cancer tissue compared with surrounding
non-neoplastic tissues. Meanwhile, a further significant
decrease of C3b deposition could be demonstrated in
human cervical cancer tissues. This finding suggested that
DAF and MCP may play an important role in survival of
human cervical cancer cells.Page 3 of 8
(page number not for citation purposes)
BMC Cancer 2009, 9:384 http://www.biomedcentral.com/1471-2407/9/384
Page 4 of 8
(page number not for citation purposes)
The DAF and MCP expression levels and C3b deposition in cancer tissueFigure 1
The DAF and MCP expression levels and C3b deposition in cancer tissue. A: Relative DAF expression levels were 
shown between human cervical cancer tissues (T) and surrounding non-neoplastic tissues (N). The expression of DAF mRNA 
and protein was measured by Real-time PCR and Western blot respectively, The DAF gene in human cervical cancer tissue 
was overexpressed. Results shown are the mean ± SD of three independent transfections (n = 3), each conducted in triplicate. 
B: Relative MCP expression levels were shown between human cervical cancer tissues (T) and surrounding non-neoplastic tis-
sues (N). The expression of MCP mRNA and protein was measured by Real-time PCR and Western blot respectively, The 
MCP gene in human cervical cancer tissue was overexpressed. Results shown are the mean ± SD of three independent trans-
fections (n = 3), each conducted in triplicate. C: Deposition of opsonizing C3 split products were shown between human cer-
vical cancer tissues and surrounding non-neoplastic tissues (measured as common C3b moiety). Data are presented as means 
± SD of two independent experiments. Student's t-test: N versus T. **p < 0.01; *p < 0.05, respectively.
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deposition
In this experiment, MCP and DAF protein were studied
together. As shown in Figure 2, MCP alone on the cell sur-
face conferred minimal inhibition of C3b deposi-
tion(5.8%), as did a range of limiting DAF
concentrations(0-11.3% inhibition). In contrast, inhibi-
tion increased dramatically when both proteins were
incorporated into the cells (up to 53.3%). With the fixed
limiting dose of MCP, inhibition was again dependent on
the concentration of the DAF added.
Functional analysis of MCP and/or DAF shRNA-mediated 
inhibition of MCP and/or DAF expression
Because MCP and DAF are regulators of the early comple-
ment pathway, their knock-down was also expected to
improve C3 opsonization of tumor cells. Therefore, C3
split product deposition (measured as C3b) was analysed
on MCP and/or DAF-deficient tumor cells following com-
plement activation. Tumor cells were transfected with
negative shRNA, MCP shRNA, DAF shRNA and MCP
shRNA+ DAF shRNA respectively. The results showed
improved C3b opsonization upon MCP and DAF suppres-
sion, where down-regulation of MCP and DAF did
enhance complement-mediated cytotoxicity significantly
(Figure 3A).
A further significant augmentation of complement-medi-
ated cytotoxicity could be demonstrated in ME180 cells
upon simultaneous transfection of MCP shRNA+ DAF
shRNA. Compared to complement-mediated cytotoxicity
following knock-down of MCP (most potent single
effect), a combined inhibition of MCP and DAF expres-
sion further enhanced significantly complement-medi-
ated cytotoxicity of ME180 cells by 25%(Figure 3B)
The effect of human cervical cancer cells viability, 
migration and proliferation induced by down-expression of 
MCP and/or DAF
To investigate the effect of DAF and MCP on human cer-
vical cancer cells viability, migration and proliferation,
ME180 was transfected with negative shRNA, MCP
shRNA, DAF shRNA and MCP shRNA+ DAF shRNA
respectively. Cell viability was determined by WST-1
assay. As shown in Figure 4A, MCP shRNA+ DAF shRNA
can significantly decrease cell viability, compared with
negative shRNA, meanwhile, the viability of cells in MCP
shRNA group and DAF shRNA group had slight change
compared with MCP shRNA+ DAF shRNA group. The
results indicated that cooperative inhibition of DAF and
MCP genes resulted in dramatically decreasing viability of
ME180 cells.
To determine whether DAF and MCP involved in regula-
tion of cell migration, ME180 was transfected with nega-
tive shRNA, MCP shRNA, DAF shRNA and MCP shRNA+
DAF shRNA respectively. The number of migrated cell
treated with MCP shRNA+ DAF shRNA was significantly
lower than that in negative shRNA (p < 0.01). The silence
of DAF and MCP synergistically can significant decrease
the migration of ME180 cells. The numbers of migrated
cells were also differences in MCP shRNA and DAF shRNA
group when compared with MCP shRNA+ DAF shRNA
group (p < 0.05), which indicated enhancing effect of DAF
and MCP on cell migration.
As shown in Figure 4C, the exposure of MCP shRNA+ DAF
shRNA decreased the proliferation of cervical cancer cell.
There was an apparent decrease in ME180 DNA synthesis,
exposed to MCP shRNA+ DAF shRNA for 24 h after the
initial manipulation. The effect of negative shRNA, MCP
shRNA and DAF shRNA exposure on cell proliferation was
also determined. MCP shRNA+ DAF shRNA can signifi-
cantly decrease the proliferation of cervical cancer cell, as
compared with negative shRNA, MCP shRNA and DAF
shRNA group respectively. As above, MCP and DAF can
dramatically inhibit the proliferation of cervical cancer
cell in a cooperative fashion.
Discussion
The membrane attack complex inhibitory protein DAF
and MCP are key members of the family of complement
regulatory proteins. Due to the expression of membrane-
bound complement regulatory proteins, complement
deposition on neoplastic cells is limited and therefore not
sufficient to induce potent tumour cell killing [9]. Silenc-
ing of complement regulatory proteins has been shown to
sensitize tumour cells to complement attack [10]. There-
fore, we applied a shRNA strategy to inhibit specifically
the expression of DAF and MCP aiming at better employ-
ment of complement for tumour cell destruction.
C3b depositionFigur  2
C3b deposition. Cooperative inhibition of C3b deposition 
by DAF and MCP was shown in this experiment. At the low 
levels tested, DAF had only minor effects on C3b deposition 
when present alone. However, when present with low levels 
of MCP, the inhibition dramatically increased. For each 
experiment, the data given are the mean ± SD, where n = 3.Page 5 of 8
(page number not for citation purposes)
BMC Cancer 2009, 9:384 http://www.biomedcentral.com/1471-2407/9/384Numerous studies have been performed on the comple-
ment regulatory proteins in primary tumors and in tumor
cell lines, in an attempt to clarify their significance to can-
cer immunoresistance. The fact that most cancers, inde-
pendent of their tissue origin, express at least two if not
three complement regulatory proteins, is perhaps not sur-
prising considering the wide tissue distribution of DAF
and MCP [11]. Li et al [12] examined colorectal and gas-
tric carcinomas and osteosarcoma and found increased
expression of DAF, whereas Kiso et al [13] found
increased expression of both DAF and MCP in intestinal
type gastric carcinoma. In ovarian cancer, DAF and MCP
were more heterogeneously expressed and resistance to
complement correlated in these cells with high level of
DAF and MCP expression [14]. In this study, we detected
the expression of DAF and MCP protein in cervical cancer
tissue by Western blot. Increasing changes in DAF and
MCP protein were observed, the expression of DAF and
MCP were significantly increased in human cervical can-
cer tissue compared with surrounding non-neoplastic tis-
sues, Meanwhile, a further significant decrease of C3b
deposition could be demonstrated in human cervical can-
cer tissues. This finding suggested that DAF and MCP may
play an important role in survival of human cervical can-
cer cells.
Although DAF and MCP each have been studied exten-
sively, no investigations have focused on whether the two
proteins interact in providing optimal protection of self
cells from autologous complement despite the fact that
nearly all cells express both proteins. Using the above
experimental system with incorporated DAF and MCP in
ME180 cells, we demonstrated that the two regulators
work synergistically on the cell surface in preventing alter-
native pathway-mediated C3b deposition. The magnitude
of the inhibition of C3b uptake in the presence of the two
proteins compared to each protein individually was strik-
ing. At higher concentrations of the proteins, this cooper-
ative inhibition reached 53-72% as compared to 0-11%
for each protein when the proteins were incorporated
individually at the same concentrations.
Functional studies were performed to evaluate comple-
ment resistance of tumour cells after shRNA-mediated
knock-down of DAF and/or MCP expression. The most
striking effects were found that CDC was increased about
67% after inhibition of DAF and MCP; 39% and 36%
increased CDC were apparent in MCP or DAF-deficient
ME180 cells respectively. In contrast to the DAF and MCP
shRNA approach, silencing DAF or MCP by shRNA had
only a weak effect on ME180 cells and negative shRNA
had no effect at all. It therefore appears that, in human
cervical tumours, synergistically silencing DAF and MCP
may be more effectively inhibit complement-mediated
cytotoxicity.
The expression of DAF and MCP were significantly
increased in human cervical cancer tissue. This finding
suggested that DAF and MCP may play important roles in
C3b deposition and complement-mediated cytotoxicityFigur  3
C3b deposition and complement-mediated cytotox-
icity. A: Deposition of opsonizing C3 split products on DAF- 
and/or MCP-deficient tumour cells (measured as common 
C3b moiety). Tumor cells were transfected with negative 
shRNA, MCP shRNA, DAF shRNA and MCP shRNA+ DAF 
shRNA respectively, as indicated in the diagram. Following 
complement activation by polyclonal tumor-specific antibod-
ies, deposited C3b molecules were quantified by flow cytom-
etry. Data are shown from one representative experiment 
(of three). Negative shRNA, MCP shRNA, DAF shRNA ver-
sus MCP shRNA+ DAF shRNA. **p < 0.01; MCP shRNA, 
DAF shRNA versus negative shRNA. *p < 0.05, respectively. 
B: Complement-dependent cytolysis of DAF- and MCP-defi-
cient ME180 cells. Tumor cells were transfected with nega-
tive shRNA, MCP shRNA, DAF shRNA and MCP shRNA+ 
DAF shRNA respectively, as indicated in the diagram. 72 h 
later, complement-dependent cytolysis of ME180 cells was 
measured. Data are presented as means ± SD of triplicates of 
one representative experiment (of three). DAF shRNA, MCP 
shRNA, MCP shRNA+ DAF shRNA versus negative shRNA. 
**p < 0.01; ***p < 0.001; MCP shRNA, DAF shRNA versus 
MCP shRNA+ DAF shRNA.*p < 0.05, respectively.Page 6 of 8
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Human cervical cancer cells viability, migration and proliferationFigure 4
Human cervical cancer cells viability, migration and proliferation. ME180 cells (3 × 104/ml) were treated with nega-
tive shRNA, MCP shRNA, DAF shRNA and MCP shRNA+ DAF shRNA respectively in this experiment. (A): The ME180 cells 
viability was detected via WST-1 assay. Sample absorbance was analyzed using a bichromatic ELISA reader at 450 nm. **p < 
0.01 versus MCP shRNA+ DAF shRNA, #p < 0.05 versus MCP shRNA+ DAF shRNA. (B): The migration of ME180 cells was 
measured by Transwell assay. The migrated cells were counted microscopically (400×) in five different fields per filter. **p < 
0.01 versus MCP shRNA+ DAF shRNA, #p < 0.05 versus MCP shRNA+ DAF shRNA. (C) to observe the measuring 3H-thymi-
dine incorporated into DNA over the last 18 h of the final incubation. Results were mean ± SD from 3 independent experi-
ments. **p < 0.01 versus MCP shRNA+ DAF shRNA, #p < 0.05 versus MCP shRNA+ DAF shRNA.
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the survival of the human cervical cancer cells. According
to our study (Figure 4A, B, and 4C), Cooperative inhibi-
tion the expression of DAF and MCP genes might decrease
viability, migration and proliferation of ME180 cells. DAF
and MCP may protect tumor from accidental injury by
activated complement, also confer resistance on cancer
cells. It seemed that DAF and MCP promotes cell viability,
migraton and proliferation, even though the exact mech-
anism should be studied further. In the future trial we
should provide a detailed analysis of complement regula-
tory protein expression on HPV infected and not infected
human cervical cancer cells. We should also examine HPV
infected and not infected premalignant cervical lesions
and primary cervical squamous carcinomas to determine
whether changes in the expression of these proteins are
associated with the development of cervical disease.
Conclusion
In conclusion, we were able to identify potent shRNA for
efficient down-regulation of DAF and MCP expression on
tumour cells. Knock-down of both surface-regulators
clearly sensitized tumour cells to complement attack. This
has been proved by analysis of complement-mediated
cytotoxicity and also by investigation of C3b-deposition.
The present data indicated that synergistical silencing DAF
and MCP significantly decreased the human cervical can-
cer cell viability, migraton and proliferation. These data
indicated that combined DAF and MCP shRNA described
in this study may offer an additional alternative to
improve the efficacy of antibody-and complement-based
cancer immunotherapy in the future.
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